Therapeutic insights into “awakening the sleeping angel” in p53-mutated human tumors: MiRNA-214 increases the expression of tumor suppressor p53 homologue TAp73 and inhibits tumorigenesis via down regulation of its target gene, 31/3/2015, 21.36

Small molecule-based therapy for metastatic tumors: Nutlin inhibits epithelial-mesenchymal transition and cancer cell proliferation via down regulation of GLUT3, 31/March/2015, 21.19
March 31, 2015
Natural product-based therapy for regional enteritis disease: Oleic acid, the main component of Neem oil, increases the expression of immunosuppressive cytokine TGF-β1 and inhibits the progression of regional enteritis disease via up regulation of its target gene, 31/March/2015, 22.25
March 31, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Significance: Cancer suppressor p53 is mutated in more than 50% of different human cancers.  This study suggests, for the first time, a therapeutic strategy as to how mutant p53 expressing human cancers can be cured by activating its “unmutated homologous proteins”, such as TAp73. MiRNA-214, by decreasing the expression of its target gene, it may increase the expression of p53 homologue TAp63γ. Thereby, it may promote tumor suppression. Together, this study suggests a therapeutic strategy as to how one can cure cancer, by activating an alternative cancer suppressor, with an miRNA-214. Thus, pharmacological formulations encompassing “MiRNA-214 activators”  can be used to inhibit the progression of human tumors, including p53-mutated human tumors.

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500*

Undisclosed information: How MiRNA-214 increases the expression of TAp73

* Research cooperation

CitationBoominathan, Therapeutic insights into “awakening the sleeping angel” in p53-mutated human tumors: MiRNA-214 increases the expression of tumor suppressor p53 homologue TAp73 and inhibits tumorigenesis via down regulation of its target gene, 31/3/2015, 21.40, 31/3/2015, 21.36, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.